Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 4/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6853427 | 1.00 | ATM (0.44) | ATMAPPAKT1CDK2CDK7 | |
| SCHEMBL6853498 | 0.86 | NTRK1 (0.47) | AKT1CDK2CDK7RENSCN9A | |
| SCHEMBL6853500 | 0.86 | NTRK1 (0.47) | AKT1CDK2CDK7RENSCN9A | |
| SCHEMBL6849856 | 0.82 | ATM (0.42) | ATMAPPSCN9AACECTSK | |
| SCHEMBL6849858 | 0.82 | ATM (0.42) | ATMAPPSCN9AACECTSK | |
| SCHEMBL6833591 | 0.80 | PPARA (0.39) | ATMAKT1CDK2CDK7CTSS | |
| SCHEMBL6833590 | 0.80 | PPARA (0.39) | ATMAKT1CDK2CDK7CTSS | |
| SCHEMBL4764962 | 0.79 | ATM (0.39) | ATMAPPAKT1CYP3A4ACE | |
| SCHEMBL5474447 | 0.79 | ATM (0.39) | ATMAPPAKT1CYP3A4ACE | |
| SCHEMBL4764967 | 0.79 | ATM (0.39) | ATMAPPAKT1CYP3A4ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | ATM 353/4885APP 4630/4885AKT1 119/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | ATM 353/4885APP 4630/4885AKT1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.